66021-71-4

Basic information

• Product Name: 1-(1-azidocyclohexyl)benzene
• Synonyms: 1-(1-azidocyclohexyl)benzene
• CAS NO: 66021-71-4
• Molecular Weight: 201.271
• Mol File: 66021-71-4.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: 1-(1-azidocyclohexyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-azidocyclohexyl)benzene(66021-71-4)
• EPA Substance Registry System: 1-(1-azidocyclohexyl)benzene(66021-71-4)

Safety Data

• Hazardous Substances Data: 66021-71-4(Hazardous Substances Data)

Upstream product

• 591-50-4 iodobenzene 
• 827-52-1 1-phenyl-1-cyclohexane 
• 771-98-2 1-Phenylcyclohexene 
• 1589-60-2 1-phenylcyclohexanol 
• 108-94-1 cyclohexanone 

Downstream Products

• 2201-24-3 1-phenylcyclohexylamine 
• 1333494-91-9 N-((S)-2-amino-3-((S)-1-((S)-1-((2S,3R)-3-hydroxy-4-oxo-1-phenyl-4-(1-phenylcyclohexylamino)butan-2-ylamino)-4-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxobutan-2-ylamino)-3-oxopropyl)-5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamide 
• 1333494-92-0 N-((S)-2-amino-3-((S)-1-((S)-3-cyclohexyl-1-((2S,3R)-3-hydroxy-4-oxo-1-phenyl-4-(1-phenylcyclohexylamino)butan-2-ylamino)-1-oxopropan-2-ylamino)-3-methyl-1-oxobutan-2-ylamino)-3-oxopropyl)-5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamide 
• 1333494-93-1 N-((S)-2-amino-3-((S)-1-((S)-1-((2S,3R)-3-hydroxy-4-oxo-1-phenyl-4-(1-phenylcyclohexylamino)butan-2-ylamino)-4-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxobutan-2-ylamino)-3-oxopropyl)-2,5-dihydroxybenzamide 
• 1333494-94-2 N-((S)-2-amino-3-((S)-1-((S)-3-cyclohexyl-1-((2S,3R)-3-hydroxy-4-oxo-1-phenyl-4-(1-phenylcyclohexylamino)butan-2-ylamino)-1-oxopropan-2-ylamino)-3-methyl-1-oxobutan-2-ylamino)-3-oxopropyl)-2,5-dihydroxybenzamide 

Relevant articles and documents

Spiro [benzo [c] aza-1, 1 '-cyclohexyl]-3-ketone compound

The invention belongs to the technical field of medicines, relates to a compound with anti-tumor activity and a specific chemical structure, and particularly relates to a 4, 5-dihydrospiro [benzo [c] aza-1, 1 '-cyclohexyl]-3 (2H)-ketone compound as well as a preparation method and application of the 4, 5-dihydrospiro [benzo [c] aza-1, 1'-cyclohexyl]-3 (2H)-ketone compound. The structural general formula of the compound is shown in the specification, wherein an R group on an a benzene ring is substituted by a 2-position, 3-position or 4-position monosubstituted fluorine atom, methyl, chlorine atom, methoxyl, bromine atom or hydrogen atom. Pharmacological studies show that the compound provided by the invention has certain inhibitory activity on human colon cancer HCT-116 cells, can be used for preparing antitumor drugs, and opens up a new way for deep research and development of tumor drugs in the future. The preparation method provided by the invention is simple and feasible, relatively high in yield and easy for large-scale production.

Mangana(iii/iv)electro-catalyzed C(sp3)-H azidation

Manganaelectro-catalyzed azidation of otherwise inert C(sp3)-H bonds was accomplished using most user-friendly sodium azide as the nitrogen-source. The operationally simple, resource-economic C-H azidation strategy was characterized by mild reaction conditions, no directing group, traceless electrons as the sole redox-reagent, Earth-abundant manganese as the catalyst, high functional-group compatibility and high chemoselectivity, setting the stage for late-stage azidation of bioactive compounds. Detailed mechanistic studies by experiment, spectrophotometry and cyclic voltammetry provided strong support for metal-catalyzed aliphatic radical formation, along with subsequent azidyl radical transfer within a manganese(iii/iv) manifold.

Design, synthesis and biological evaluation of homoerythrina alkaloid derivatives bearing a triazole moiety as PARP-1 inhibitors and as potential antitumor drugs

A series of homoerythrina alkaloid derivatives containing a 1,2,3-triazole moiety as PARP-1 inhibitors were designed and synthesized. And their anti-proliferative activity was further evaluated. Compound 10n had excellent activity to inhibit proliferation of A549 cells (IC50 = 1.89 μM), which was higher than harringtonine (IC50 = 10.55 μM), pemetrexed (IC50 = 3.39 μM), and rucaparib (IC50 = 4.91 μM). Furthermore, the selectivity index of compound 10n was higher than rucaparib and pemetrexed for lung cancer cells. Flow cytometry analysis showed that compound 10n significantly arrested the cell cycle in the S phase, then induced apoptosis of A549 cells (apoptosis rate is 46%), which effectively inhibited cell proliferation. Simultaneously, western blot analysis revealed that compound 10n could prevent the biosynthesis of PAR. Further analysis results revealed that compound 10n could inhibit the expression of cyclin A, down-regulate the expression of bcl-2/bax, activate caspase-3, and ultimately induce apoptosis of A549 cells. All the results indicated that compound 10n had potential research value as a novel PARP-1 inhibitor in antitumor, and it provided a new reference for further development of PARP-1 inhibitors.